Kura Oncology, Inc. (NASDAQ:KURA) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.

Several other analysts have also issued reports on KURA. Leerink Swann reiterated an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Zacks Investment Research downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and set a $7.25 price target on the stock. in a report on Wednesday, August 23rd. Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Wednesday, June 28th. Finally, Cann reissued a “buy” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Monday, May 15th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $14.15.

Kura Oncology (NASDAQ KURA) traded up 72.26% during mid-day trading on Friday, hitting $11.80. 20,286,638 shares of the stock were exchanged. The company’s market capitalization is $235.86 million. The stock’s 50-day moving average is $7.97 and its 200 day moving average is $8.71. Kura Oncology has a 52 week low of $4.00 and a 52 week high of $13.80.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. On average, analysts anticipate that Kura Oncology will post ($1.55) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/09/kura-oncology-inc-kura-raised-to-hold-at-valuengine.html.

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. purchased a new position in shares of Kura Oncology in the 1st quarter worth about $533,000. Renaissance Technologies LLC boosted its holdings in shares of Kura Oncology by 158.8% in the 1st quarter. Renaissance Technologies LLC now owns 79,200 shares of the company’s stock worth $697,000 after buying an additional 48,600 shares during the last quarter. Alethea Capital Management LLC boosted its holdings in shares of Kura Oncology by 128.1% in the 2nd quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock worth $1,798,000 after buying an additional 108,577 shares during the last quarter. Nationwide Fund Advisors purchased a new position in shares of Kura Oncology in the 1st quarter worth about $136,000. Finally, Segantii Capital Management Ltd purchased a new position in shares of Kura Oncology in the 1st quarter worth about $120,000. 39.07% of the stock is currently owned by institutional investors.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.